MHC-I genotype and tumor mutational burden predict response to immunotherapy

MHC-I genotype and tumor mutational burden predict response to immunotherapy

Abstract Background Immune checkpoint blockade (ICB) with antibodies inhibiting cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed cell death protein-1 (PD-1) (or its ligand (PD-L1)) can stimulate immune responses against cancer and have revolutionized the treatment of tumors. The i...

Full description

Bibliographic Details
Main Authors: Aaron M. Goodman, Andrea Castro, Rachel Marty Pyke, Ryosuke Okamura, Shumei Kato, Paul Riviere, Garrett Frampton, Ethan Sokol, Xinlian Zhang, Edward D. Ball, Hannah Carter, Razelle Kurzrock
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Genome Medicine
Subjects:
MHC-I
TMB
Biomarkers
Checkpoint blockade
Online Access:http://link.springer.com/article/10.1186/s13073-020-00743-4

Internet

http://link.springer.com/article/10.1186/s13073-020-00743-4

Similar Items